OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition

• 成果类型: Article
• 署名作者: Nan, Yabing; Wu, Xiaowei; Luo, Qingyu; Chang, Wan; Zhao, Pengfei; Zhang, Lingqiang; Liu, Zhihua
• 署名单位: Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Cancer Institute & Hospital - CAMS; Harvard University; Harvard Medical School; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard University Medical Affiliates; Dana-Farber Cancer Institute; Harvard Medical School
• 刊物名称: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
• ISSN/ISSBN: 0027-10688
• DOI: 10.1073/pnas.2315348121
• 发表日期: 2024-05-01
• 关键词: hypoxia-inducible factors; STABILITY; expression; hallmarks; complex; vhl

摘要

Ovarian cancer is an aggressive gynecological tumor characterized by a high relapse rate and chemoresistance. Ovarian cancer exhibits the cancer hallmark of elevated glycolysis, yet effective strategies targeting cancer cell metabolic reprogramming to overcome therapeutic resistance in ovarian cancer remain elusive. Here, we revealed that epigenetic silencing of Otubain 2 ( OTUB2 ) is a driving force for mitochondrial metabolic reprogramming in ovarian cancer, which promotes tumorigenesis and chemoresistance. Mechanistically, OTUB2 silencing destabilizes sorting nexin 29 pseudogene 2 (SNX29P2), which subsequently prevents hypoxia - inducible factor - 1 alpha (HIF - 1 alpha ) from von Hippel-Lindau tumor suppressor - mediated degradation. Elevated HIF - 1 alpha activates the transcription of carbonic anhydrase 9 ( CA9 ) and drives ovarian cancer progression and chemoresistance by promoting glycolysis. Importantly, pharmacological inhibition of CA9 substantially suppressed tumor growth and synergized with carboplatin in the treatment of OTUB2 - silenced ovarian cancer. Thus, our study highlights the pivotal role of OTUB2/SNX29P2 in suppressing ovarian cancer development and proposes that targeting CA9 - mediated glycolysis is an encouraging strategy for the treatment of ovarian cancer.